Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Free Report) – Equities research analysts at HC Wainwright lifted their FY2028 earnings per share (EPS) estimates for Compass Pathways in a report released on Monday, November 9th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $0.10 per share for the year, up from their prior forecast of ($0.23). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Compass Pathways’ FY2029 earnings at $1.92 EPS and FY2030 earnings at $4.21 EPS.
Compass Pathways (NASDAQ:CMPS – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.08.
Several other brokerages have also issued reports on CMPS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a research note on Thursday, October 15th. BTIG Research reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Compass Pathways in a research note on Tuesday, November 3rd. Royal Bank Of Canada reiterated an “outperform” rating on shares of Compass Pathways in a research report on Wednesday, November 4th. Wells Fargo & Company lowered their price target on shares of Compass Pathways from $13.00 to $10.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 4th. Finally, Morgan Stanley upped their price target on shares of Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Compass Pathways currently has a consensus rating of “Moderate Buy” and an average price target of $23.14.
Check Out Our Latest Stock Analysis on CMPS
Compass Pathways Price Performance
Shares of Compass Pathways stock opened at $8.27 on Tuesday. The firm has a market capitalization of $1.17 billion, a PE ratio of -2.37 and a beta of 2.43. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.35. Compass Pathways has a 12 month low of $4.88 and a 12 month high of $15.87. The business’s 50-day moving average price is $11.79 and its 200-day moving average price is $10.47.
Institutional Trading of Compass Pathways
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ancora Advisors LLC bought a new stake in Compass Pathways in the second quarter valued at $43,000. EverSource Wealth Advisors LLC increased its position in Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after purchasing an additional 1,920 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Compass Pathways in the 3rd quarter worth $85,000. Parallel Advisors LLC raised its holdings in Compass Pathways by 8,450.6% in the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after purchasing an additional 7,183 shares in the last quarter. Finally, North Star Investment Management Corp. lifted its position in shares of Compass Pathways by 23.9% in the 3rd quarter. North Star Investment Management Corp. now owns 9,317 shares of the company’s stock worth $116,000 after purchasing an additional 1,800 shares during the period. Hedge funds and other institutional investors own 46.19% of the company’s stock.
About Compass Pathways
Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.
See Also
- Five stocks we like better than Compass Pathways
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
